Innovative medicine sector continues to recover, and the total product revenue of Zengding Pharmaceutical in the third quarter increased by over 20% year-on-year
海角七号
发表于 2023-11-9 19:04:29
237
0
0
On November 8th, Zaiding Pharmaceutical released its Q3 financial report. Data shows that the total revenue of Zaiding Pharmaceutical's products in the third quarter was 69.228 million US dollars, a year-on-year increase of 21.53%, and a year-on-year increase of 27% calculated at a fixed exchange rate. Mainly due to the increase in sales, the official launch of the newly approved product Weiweijia, and a decrease in the negative impact of the COVID-19 pandemic.
Financial report data shows that compared to the same period in 2022, several heavyweight products of Zaiding Pharmaceutical have achieved strong growth.
In the third year of being included in the national medical insurance drug catalog, Zele continued to maintain its position as a leading hospital sales PARP inhibitor in the field of ovarian cancer in mainland China, with product revenue increasing from $39.2 million to $41.6 million. The revenue of Epshield products increased from $10.7 million to $11.6 million, thanks to the improved accessibility of the product for self funded patients. In addition, the revenue of the two products, Qingle and Newzele, which have already been included in medical insurance, both achieved year-on-year growth.
In September 2023, Weiweijia& was used in combination with conventional treatment drugs to treat adult gMG patients with acetylcholine (AChR) antibody positivity; Reg; (Agamod) α Injection) has been launched in mainland China, and the number of commercial products from Zaiding Pharmaceutical has increased to 5. In just one month of commercialization, Wei Weijia achieved sales revenue of $4.9 million.
In addition to existing products that have already been launched, Zaiding Pharmaceutical is still actively exploring the multiple indications coverage of products that have already been launched, as well as promoting the further implementation of research and development pipelines.
The company is also continuing to promote the development of its subsequent dosage forms for the heavyweight new drug Agamod in the field of self immunity, which has received considerable market attention. Zaiding Pharmaceutical stated that its drug application for the treatment of systemic myasthenia gravis is expected to be approved by the National Drug Administration in 2024.
Another product in the pipeline of the already launched products of Zaiding Pharmaceutical, tumor electric field therapy, is expected to receive multiple indications for market application and disclosure of main clinical research data by the end of 2023 and 2024.
In addition to exploring multiple indications for products that have already been launched, Zaiding Pharmaceutical also has multiple products in the fields of tumors, Alzheimer's disease and psychiatric disorders (ADP), which are about to usher in multiple important milestones and the latest research results in the coming year.
Founder of Zaiding Pharmaceutical Dr. Du Ying, Chairman and CEO, stated, "In the third quarter of 2023, we achieved multiple important milestones, including the National Drug Administration (NMPA) We are reviewing and approving multiple new drug launch applications from our company and conducting critical clinical studies on drugs with significant market potential. We have a good advantage in accelerating our pipeline progress, expanding our commercial product portfolio, and bringing more benefits to patients worldwide
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Extreme Krypton: The right-hand drive version of Extreme Krypton X has launched pre-sale plans in Thailand and will be delivered in the third quarter
- TSMC: 7 nanometers and more advanced processes accounted for 65% of the total wafer revenue in the first quarter
- TSMC: 7 nanometers and more advanced processes accounted for 65% of the total wafer revenue in the first quarter
- Yum! Brands China's total revenue reached a new high in the first quarter, with an expected net increase of 1500 to 1700 stores within the year
- Disney's global experience sector will invest 60 billion US dollars. Shanghai Disneyland had over 13 million visitors last year
- Third quarter sales guidance lower than market expectations, ASML falls more than 4%
- ASML's Q3 performance outlook falls short of expectations, with an overnight drop of 12.74% | From Wall Street to Lujiazui
- Tesla has fallen out of favor? California registration volume dropped by 24% in Q2 and has been declining for three consecutive quarters
- Sohu's total revenue in the second quarter increased by 13% to $172 million, exceeding expectations for online games
- InterContinental Hotels' total revenue for the first half of 2024 was $2.322 billion, a year-on-year increase of 4%
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏
-
10月1日、極クリプトン自動車が発表したデータによると、今年第3四半期に新車が累計14万2900台納入され、前年同期比81%増となった。このうち、9月に新車を納入したのは2万13万人で、前年同期比77%、前月比18%増だっ ...
- 内托体头
- 3 小时前
- 支持
- 反对
- 回复
- 收藏